Total Payments
$5,094
2024 Payments
$1,150
Companies
26
Transactions
155
Medicare Patients
606
Medicare Billing
$112,677
Payment Breakdown by Category
Food & Beverage$5,094 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,094 | 155 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,104 | 25 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $745.08 | 16 | $0 (2024) |
| ABBVIE INC. | $484.43 | 35 | $0 (2024) |
| Lilly USA, LLC | $464.27 | 19 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $450.89 | 5 | $0 (2017) |
| Amgen Inc. | $385.07 | 13 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $231.26 | 4 | $0 (2024) |
| Allergan Inc. | $231.16 | 3 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $184.26 | 4 | $0 (2024) |
| Abbott Laboratories | $158.73 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,150 | 40 | ABBVIE INC. ($241.45) |
| 2023 | $344.35 | 26 | AbbVie Inc. ($132.53) |
| 2022 | $628.04 | 18 | Novo Nordisk Inc ($156.20) |
| 2021 | $607.17 | 11 | AstraZeneca Pharmaceuticals LP ($388.28) |
| 2020 | $296.35 | 11 | Novo Nordisk Inc ($143.43) |
| 2019 | $433.52 | 11 | Novo Nordisk Inc ($292.95) |
| 2018 | $158.57 | 2 | Amgen Inc. ($119.57) |
| 2017 | $1,476 | 36 | SANOFI-AVENTIS U.S. LLC ($450.89) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $19.80 | General |
| Category: Cardiovascular Device | ||||||
| 11/20/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Inflammation | ||||||
| 10/31/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: NEUROLOGY | ||||||
| 10/08/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $121.65 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $23.47 | General |
| Category: Cardiovascular Device | ||||||
| 08/27/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Obesity | ||||||
| 08/27/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $9.01 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Inflammation | ||||||
| 08/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.67 | General |
| Category: NEUROSCIENCE | ||||||
| 07/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $2.75 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $5.64 | General |
| Category: Diabetes | ||||||
| 07/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.28 | General |
| Category: NEUROSCIENCE | ||||||
| 06/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Cardio-renal | ||||||
| 06/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.54 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $109.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.72 | General |
| Category: NEUROSCIENCE | ||||||
| 05/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Cardio-renal | ||||||
| 04/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $120.82 | General |
| Category: Cardio-renal | ||||||
| 04/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 147 | 316 | $39,988 | $25,877 |
| 2022 | 5 | 137 | 306 | $44,051 | $28,345 |
| 2021 | 3 | 70 | 239 | $37,660 | $23,391 |
| 2020 | 8 | 252 | 564 | $68,382 | $35,063 |
Total Patients
606
Total Services
1,425
Medicare Billing
$112,677
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 212 | $29,947 | $19,862 | 66.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 23 | $4,281 | $3,025 | 70.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 41 | $3,969 | $2,561 | 64.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 22 | 25 | $1,341 | $266.64 | 19.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 15 | $450.00 | $163.20 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 70 | 234 | $33,177 | $22,155 | 66.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 25 | $4,829 | $3,345 | 69.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $2,911 | $1,651 | 56.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $1,790 | $938.82 | 52.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 21 | 24 | $1,344 | $254.89 | 19.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 205 | $29,426 | $18,895 | 64.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 23 | $4,945 | $3,138 | 63.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $3,289 | $1,358 | 41.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 77 | 322 | $45,712 | $25,608 | 56.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 36 | $9,128 | $4,049 | 44.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 25 | 25 | $5,832 | $2,619 | 44.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 21 | $2,118 | $1,252 | 59.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 47 | 64 | $3,048 | $798.57 | 26.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 27 | 53 | $1,969 | $488.53 | 24.8% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2020 | 16 | 22 | $361.02 | $175.72 | 48.7% |
| 81002 | Urinalysis, manual test | Office | 2020 | 18 | 21 | $213.84 | $72.03 | 33.7% |
About Dr. Saul Amber, MD
Dr. Saul Amber, MD is a Internal Medicine healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1609921915.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Saul Amber, MD has received a total of $5,094 in payments from pharmaceutical and medical device companies, with $1,150 received in 2024. These payments were reported across 155 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($5,094).
As a Medicare-enrolled provider, Amber has provided services to 606 Medicare beneficiaries, totaling 1,425 services with total Medicare billing of $112,677. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Scottsdale, AZ
- Active Since 01/24/2007
- Last Updated 07/21/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1609921915
Products in Payments
- SOLIQUA (Drug) $450.89
- Ozempic (Drug) $363.17
- FARXIGA (Drug) $319.52
- VRAYLAR (Drug) $296.26
- BREZTRI (Drug) $275.07
- Repatha (Biological) $241.18
- Optimizer (Device) $231.26
- MOUNJARO (Drug) $205.51
- Kerendia (Drug) $184.26
- NAMZARIC (Drug) $154.94
- Tresiba (Drug) $151.39
- TRULICITY (Drug) $144.15
- CONFIRM RX (Device) $122.66
- Victoza (Drug) $121.55
- MOVANTIK (Drug) $117.18
- CAPLYTA (Drug) $108.39
- RYBELSUS (Drug) $99.23
- Rybelsus (Drug) $79.51
- NAMENDA XR (Drug) $76.22
- UBRELVY (Drug) $71.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Scottsdale
Dr. Christina Ha, M.d, M.D
Internal Medicine — Payments: $257,547
Internal Medicine $257,547
Bassam Abu Jawdeh, Md, MD
Internal Medicine — Payments: $175,490
Internal Medicine $175,490
Dr. Thai Ho, M.d./Ph.d, M.D./PH.D
Internal Medicine — Payments: $129,128
Internal Medicine $129,128
Craig Primack, Md, MD
Internal Medicine — Payments: $107,435
Internal Medicine $107,435
Jacqueline Watchmaker, M.d, M.D
Internal Medicine — Payments: $90,176
Internal Medicine $90,176
Dr. Amar Thosani, M.d, M.D
Internal Medicine — Payments: $71,283
Internal Medicine $71,283